Agios Pharmaceuticals has released an update on its Phase 2 trial of tebapivat, a potential therapy for sickle cell disease. The announcement underscores ongoing efforts to address this rare disease and bring new options to those affected.

A new Phase 2 clinical trial is shining a spotlight on the potential benefits of Zabopegdutide for MASH patients. HistoIndex’s AI-powered analysis has revealed robust improvements in liver fibrosis, offering a promising glimpse of future treatment possibilities.

A high-risk multiple myeloma diagnosis transformed one patient’s life in December 2020. Now enrolled in a Phase 2 clinical trial, they continue to experience persistent numbness even after four years of treatment.

Actuate Therapeutics is set to present the topline results of its Phase 2 trial of elraglusib at the 2025 American Society of Clinical Oncology Annual Meeting. The oral presentation will focus on the combination of elraglusib with gemcitabine/nab-paclitaxel in the first-line treatment of metastatic pancreatic ductal adenocarcinoma.